Jackson Creek Investment Advisors LLC Makes New Investment in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Jackson Creek Investment Advisors LLC bought a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,683 shares of the company's stock, valued at approximately $991,000. Jackson Creek Investment Advisors LLC owned approximately 0.05% of Harmony Biosciences at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Harmony Biosciences by 95.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,533 shares of the company's stock worth $50,000 after buying an additional 748 shares during the period. Oakworth Capital Inc. acquired a new stake in shares of Harmony Biosciences in the third quarter valued at about $150,000. ELCO Management Co. LLC acquired a new stake in shares of Harmony Biosciences in the third quarter valued at about $210,000. Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Harmony Biosciences in the fourth quarter worth about $210,000. Finally, Raymond James & Associates acquired a new position in shares of Harmony Biosciences during the 3rd quarter worth about $216,000. Institutional investors and hedge funds own 86.23% of the company's stock.

Insider Transactions at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 11,979 shares of the business's stock in a transaction on Friday, March 15th. The stock was sold at an average price of $32.00, for a total value of $383,328.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 30.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on HRMY shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $49.00 target price on shares of Harmony Biosciences in a research report on Friday, April 12th. The Goldman Sachs Group upped their target price on shares of Harmony Biosciences from $25.00 to $28.00 and gave the company a "sell" rating in a research note on Tuesday, January 9th. Bank of America restated an "underperform" rating and issued a $30.00 price target on shares of Harmony Biosciences in a research report on Tuesday, January 2nd. Finally, Mizuho cut their price objective on shares of Harmony Biosciences from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday, February 27th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $40.63.

Harmony Biosciences Stock Performance

Harmony Biosciences stock traded up $1.66 on Tuesday, hitting $30.91. The company's stock had a trading volume of 1,739,414 shares, compared to its average volume of 392,056. The company has a fifty day moving average price of $31.24 and a 200-day moving average price of $30.01. The firm has a market cap of $1.76 billion, a P/E ratio of 14.58, a price-to-earnings-growth ratio of 0.41 and a beta of 0.73. Harmony Biosciences Holdings, Inc. has a one year low of $18.61 and a one year high of $39.26. The company has a quick ratio of 2.72, a current ratio of 2.75 and a debt-to-equity ratio of 0.38.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Thursday, February 22nd. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.74 by ($0.29). The business had revenue of $168.40 million during the quarter, compared to the consensus estimate of $168.90 million. Harmony Biosciences had a net margin of 22.16% and a return on equity of 27.49%. The business's revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.01 EPS. On average, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3 earnings per share for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.